New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
11:18 EDTNUAN, SRPT, IGT, YPF, SBGI, TLM, WMB, APC, MDTOptions with increasing implied volatility
Options with increasing implied volatility: NUAN SRPT IGT YPF SBGI TLM WMB APC MDT
News For NUAN;SRPT;IGT;YPF;SBGI;TLM;WMB;APC;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 21, 2014
08:31 EDTTLMTalisman Energy upgraded to Speculative Buy from Neutral at Global Hunter
Subscribe for More Information
08:29 EDTAPCAnadarko upgraded to Buy from Accumulate at Global Hunter
Subscribe for More Information
05:51 EDTTLMStocks with implied volatility movement; TLM BBRY
Subscribe for More Information
October 20, 2014
13:40 EDTIGT, TLMOptions with increasing implied volatility
Subscribe for More Information
13:24 EDTTLMTalisman Energy volatility elevated
Subscribe for More Information
09:09 EDTSRPTEMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
07:20 EDTMDTInternational Continence Society to hold annual meeting
ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24.
07:12 EDTMDTCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
05:49 EDTNUAN, TLMStocks with implied volatility movement; TLM NUAN
Subscribe for More Information
October 19, 2014
16:44 EDTSRPTEbola drug discovery efforts intensify, WSJ says
Subscribe for More Information
13:39 EDTSRPTCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
October 17, 2014
18:06 EDTWMBWilliams, Questar interested in QEP Resources pipeline unit, Bloomberg says
Subscribe for More Information
17:23 EDTWMBWilliams, Questar interested in QEP Resources pipeline unit, Bloomberg says
Subscribe for More Information
14:50 EDTSRPTBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTSRPTSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
09:17 EDTSRPTOn The Fly: Pre-market Movers
Subscribe for More Information
October 16, 2014
18:36 EDTSRPTOn The Fly: After Hours Movers
Subscribe for More Information
18:16 EDTSRPTSarepta up 10.6% following publication of Ebola phase 1 clinical study
16:13 EDTSRPTSarepta announces publication of Ebola, Marburg Phase I clinical study results
Sarepta Therapeutics announced the publication of results from two single ascending-dose studies that demonstrated no clinical or toxicologic safety concerns with the company’s drug candidates for the treatment of Ebola and Marburg virus, respectively. AVI-6002 for the treatment of Ebola is a combination therapy of two phosphorodiamidate morpholino oligomers, which target the viral matrix proteins VP24 and VP35, respectively. AVI-6003 for the treatment of Marburg is a combination therapy of two PMOs, which target the viral proteins VP24 and NP, respectively. These drug candidates use Sarepta’s advanced and proprietary PMOplus chemistry, which is also the basis of the company’s clinical-stage influenza drug candidate, AVI-7100. Results from previous viral challenge studies of AVI-6002 and AVI-6003 in non-human primates demonstrated prevention of disease development and death following exposure to Ebola or Marburg virus. Subsequent animal studies demonstrated that for each combination therapy, only one oligomer contributed to efficacy, and therefore, the lead drug candidates for Ebola and Marburg have since become the single compounds AVI-7537 and AVI-7288.
06:17 EDTMDTJefferies says Medtronic 'needs to do' Covidien takeover
Jefferies says it "can't see how Medtronic walks" from the Covidien (COV) takeover given how compelling the merger is. The firm confirmed with Medtronic (MDT) that nothing has changed in the company's commitment to the deal since new financing terms were announced on October 3. In Jefferies view, "Medtronic needs to do this deal." It notes the spread on the acquisition widened significantly on the news that Abbvie (ABBV) is reconsidering its acquisition of Shire (SHPG).
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use